Intraocular Pressure

TC-002, a latanoprost ophthalmic solution, met all primary and secondary endpoints in the phase 3 CLEAR pivotal trial, according to a press release from TearClear.

In the United States, we are now required by the ICD-10 system of coding to provide a seven-digit code when billing for glaucoma.

MONTEREY, Calif. — MicroPulse transscleral laser therapy delivered with a functionally and ergonomically revised probe resulted in a greater IOP-lowering effect while maintaining the safety profile of the original, according to a poster.

NEW YORK — Anterior chamber paracentesis may be an effective option to reduce IOP spikes after intravitreal injections and preserve retinal nerve fiber layer thickness, according to a study.

NEW YORK — In this Healio Video Perspective from the ASRS meeting, Christopher D. Riemann, MD, discusses phase 4 data from the PALADIN study assessing Alimera’s Iluvien implant for diabetic macular edema.

Once-daily fixed combination bimatoprost, timolol and brimonidine more effectively reduced peak IOP compared with a twice-daily regimen in patients with primary open-angle glaucoma, according to a study in the Journal of Glaucoma.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Michael A. Singer, MD, discusses phase 3 data from the PALADIN study.

WASHINGTON — In this Healio Video Perspective from the American Society of Cataract and Refractive Surgery meeting, Nir Shoham-Hazon, MD, discusses a study showing micropulse laser treatment to be safe and effective in treating glaucoma.

WASHINGTON — Real-world data show that patients who underwent combined Hydrus microstent implantation and cataract surgery had improved IOP and were on fewer medications at 12 months.

WASHINGTON — Take-home devices can provide IOP monitoring over longer periods of time and give physicians a better understanding of their patients’ glaucoma progression.